clenbuterol has been researched along with salmeterol xinafoate in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Johnson, M | 1 |
| Moore, NG; Pegg, GG; Sillence, MN | 1 |
| Argilés, JM; Carbó, N; González, O; Llovera, M; López-Soriano, FJ; López-Soriano, J; Tarragó, T | 1 |
| Coldham, NG; Dave, M; Howells, LC; Lake, BG; Manchee, GR; Sauer, MJ | 1 |
| Delbeke, FT; Deventer, K; Van Eenoo, P | 1 |
| Han, SO; Koeberl, DD; Li, S | 1 |
| Albac, C; Bartesaghi, R; Emili, M; Giacomini, A; Grilli, M; Guidi, S; Potier, MC; Salvalai, ME; Stagni, F; Uguagliati, B | 1 |
1 review(s) available for clenbuterol and salmeterol xinafoate
| Article | Year |
|---|---|
The pharmacology of salmeterol.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Animals; Clenbuterol; Delayed-Action Preparations; Guinea Pigs; Humans; Isoproterenol; Muscle, Smooth; Receptors, Adrenergic, beta; Salmeterol Xinafoate | 1990 |
7 other study(ies) available for clenbuterol and salmeterol xinafoate
| Article | Year |
|---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Anabolic effects of the beta 2-adrenoceptor agonist salmeterol are dependent on route of administration.
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Animals; Appetite; Body Weight; Clenbuterol; Cyclic AMP; Dose-Response Relationship, Drug; Female; Heart; Infusion Pumps; Injections, Intraperitoneal; Muscles; Organ Size; Rats; Rats, Wistar; Salmeterol Xinafoate | 1994 |
Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth.
Topics: Adipose Tissue; Adrenergic beta-Agonists; Albuterol; Animals; Body Weight; Cachexia; Clenbuterol; Eating; Liver Neoplasms, Experimental; Male; Muscle Proteins; Muscular Atrophy; Rats; Rats, Wistar; Salmeterol Xinafoate | 1997 |
Beta2-agonist abuse in food producing animals: use of in vitro liver preparations to assess biotransformation and potential target residues for surveillance.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Biotransformation; Cattle; Clenbuterol; Coumarins; Food Contamination; Foodborne Diseases; Liver; Male; Meat Products; Microsomes, Liver; Salmeterol Xinafoate | 1999 |
Quantitative detection of salmeterol after inhalation in equine urine by liquid chromatography/tandem mass spectrometry.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Calibration; Chromatography, High Pressure Liquid; Clenbuterol; Horses; Indicators and Reagents; Quality Control; Reference Standards; Reproducibility of Results; Salmeterol Xinafoate; Spectrometry, Mass, Electrospray Ionization | 2002 |
Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
Topics: alpha-Glucosidases; Animals; Clenbuterol; Dehydroepiandrosterone; Dependovirus; Disease Models, Animal; Enzyme Replacement Therapy; Genetic Therapy; Genetic Vectors; Glycogen; Glycogen Storage Disease Type II; Humans; Mice; Mice, Knockout; Myocardium; Salmeterol Xinafoate | 2016 |
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Animals, Newborn; Clenbuterol; Dentate Gyrus; Disease Models, Animal; Down Syndrome; Female; Hippocampus; Male; Mice; Mice, Transgenic; Neurogenesis; Neurons; Salmeterol Xinafoate | 2020 |